Control group:eltrombopag

2 trials

Sponsors

Beijing Children Hospital, Capital Medical University, The First Affiliated Hospital of Zhejiang Chinese Medical University

Conditions

Chronic ITP in childrenprimary immune thrombocytopenia

Phase 4

Evaluation of the efficacy of the second-line ascending treatment strategy for children with severe chronic immune thrombocytopenia: a multicenter non-inferiority clinical study

Active, not recruitingChiCTR2100048162

Beijing Children Hospital, Capital Medical UniversityChronic ITP in children

Start: 2021-07-05Updated: 2022-03-14

Unknown Phase

Low-Dose Cyclosporine Combined with Eltrombopag in Patients with Primary Immune Thrombocytopenia Refractory or Dependent to First-Line Glucocorticoid Treatment

Active, not recruitingChiCTR2600125760

The First Affiliated Hospital of Zhejiang Chinese Medical Universityprimary immune thrombocytopenia

Start: 2026-05-31Updated: 2026-06-01

Related Papers

Rituximab-first versus eltrombopag monotherapy in pediatric persistent/chronic immune refractory thrombocytopenia after first-line therapy: a prospective multicenter cohort study.

2025-10-30